Login / Signup

Perioperative LiMAx Test Analysis: Impact of Portal Vein Embolisation, Chemotherapy and Major Liver Resection.

Felix RühlmannAzadeh AzizianChristian MoosmannMarkus BernhardtJan KeckHannah FlebbeOmar Al-BouriniAli Seif Amir HosseiniMarian GradeThomas LorfMichael GhadimiThorsten PerlJochen Gaedcke
Published in: Biomedicines (2024)
For patients undergoing MLR within the 0.5% rule, which is the clinical gold standard, the LiMAx values do not offer any additional information. Additionally, the LiMAx may have reflected liver function, but it did not deliver additional information regarding postoperative liver recovery. The clinical use of LiMAx might be relevant in selected patients beyond the 0.5% rule.
Keyphrases
  • patients undergoing
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • health information
  • healthcare
  • acute kidney injury
  • locally advanced
  • rectal cancer